Impact of Medical Technology Assessment in the National Health Directorate of the Armed Forces.
DOI:
https://doi.org/10.35954/SM2014.33.1.10Keywords:
Technology Assessment, Biomedical; Technology, High-Cost; Technology Control, BiomedicalAbstract
The permanent members of the CETM meet periodically to evaluate the applications received. These are sent by means of application forms. There are two types of forms: a) to request a specific treatment for a specific patient, b) to request the incorporation of a drug to the D.N.S.FF.AA. Therapeutic Formulary. The forms are filled out by the requesting physician with his/her data, the patient's data, the requested drug, the indication and dosage, the patient's clinical condition and other treatments he/she is receiving, as well as the scientific basis and pharmaco-economic studies that lead to the request for such treatment.
The resolution of the requests requires an exhaustive and objective analysis, based on reviews by international medical technology assessment agencies of incremental cost-effectiveness type. In addition to the bibliographic evidence, the Commission carries out, in each request for the acquisition of a high-cost pharmaceutical technology, its own incremental cost-effectiveness evaluation based on clinical evidence taken from studies designed according to the GCP-ICH (Good Clinical Practice of the International Conference on Harmonization) guidelines published in peer-reviewed journals, according to market conditions and the local health system.
In addition, an analysis of economic feasibility and sustainability over time of new pharmaceutical technologies is performed. Whenever required or pertinent, alternate members and consultants are consulted prior to the decision making process. These analyses are carried out for drugs not included in the D.N.S.FF.AA. Therapeutic Formulary and not covered by the National Resources Fund.
Received for review: June 2014.
Accepted for publication: September 2014.
Contact e-mail: festevez@adinet.com.uy
Downloads
Metrics
References
(1) Sloan FA, ed. Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge University Press, 1996.
(2) Holloway K, ed. Drug and therapeutics committees: a practical guide. 2003.
(3) WHO-CHOICE: CHOosing Interventions that are Cost Effective. World Health Organization, 2002.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
